Incyte INCY Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total revenues by Product | ||||||
| ICLUSIG | $35.46M+3.6% | $34.22M-9.0% | $37.58M+14.8% | $32.73M+10.8% | $29.54M+7.9% | |
| JAKAFI | $757.76M-8.5% | $828.24M+4.7% | $791.07M+3.6% | $763.79M+7.7% | $709.41M-8.2% | |
| JAKAVI Royalty Revenues | $105.56M-18.9% | $130.23M+3.6% | $125.65M+14.5% | $109.71M+19.1% | $92.15M-19.3% | |
| Milestone and contract revenues | $17M-83.0% | $100M+122% | $45M+800% | $5M— | $0— | |
| MINJUVI/MONJUVI | $49.23M+17.5% | $41.91M-0.2% | $41.99M+34.9% | $31.13M+5.3% | $29.55M-9.9% | |
| NIKTIMVO | $55.09M-1.7% | $56.04M+22.3% | $45.83M+26.8% | $36.15M+166% | $13.61M— | |
| OLUMIANT Royalty Revenues | $36.41M— | —— | $37.11M+10.8% | $33.48M+8.7% | $30.8M— | |
| OPZELURA | $143.02M-31.0% | $207.28M+10.3% | $187.97M+14.3% | $164.5M+38.6% | $118.71M-26.5% | |
| Other product royalty revenues | $3.25M-6.4% | $3.47M+87.1% | $1.86M+44.1% | $1.29M+1.7% | $1.27M+280% | |
| PEMAZYRE | $22.54M-3.5% | $23.35M+2.7% | $22.74M+2.5% | $22.19M+20.3% | $18.44M-20.3% | |
| TABRECTA Royalty Revenues | $5.98M-16.3% | $7.14M+9.7% | $6.51M-1.8% | $6.63M+3.4% | $6.41M+2.0% | |
| ZYNYZ | $41.39M+30.4% | $31.75M+40.0% | $22.67M+154% | $8.92M+196% | $3.01M+119% | |
| Accrued and other liabilities by Product | ||||||
| Axatilimab - Commercialization Activities | $22.5M-18.5% | $27.6M— | —— | —— | —— | |
| Axatilimab - Development Activities | $1.4M-41.7% | $2.4M— | —— | —— | —— | |
| Total revenues by Geography | ||||||
| Europe | $92.43M+21.6% | $75.99M-24.2% | $100.31M+27.2% | $78.83M+14.9% | $68.61M-22.8% | |
| Other countries | $8.78M+44.5% | $6.08M+37.7% | $4.41M+1.4% | $4.35M+59.4% | $2.73M+8.8% | |
| United States | $1.17B-17.8% | $1.42B+13.0% | $1.26B+11.4% | $1.13B+15.4% | $981.56M-9.7% | |
| PP&E (Net) by Geography | ||||||
| Other countries | $14.01M-1.7% | $14.25M+5.8% | $13.47M-3.5% | $13.95M+7.3% | $13M+11.2% | |
| Switzerland | $304.82M-1.6% | $309.8M+0.6% | $308.11M-0.7% | $310.21M+9.7% | $282.7M+1.8% | |
| United States | $401.34M-1.3% | $406.83M-14.7% | $477.06M+0.6% | $474.38M+1.0% | $469.6M-0.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Incyte break its business down?
- Incyte (INCY) reports total revenues by product across 12 parts — ICLUSIG, JAKAFI, JAKAVI Royalty Revenues, Milestone and contract revenues and MINJUVI/MONJUVI. Each is extracted from the segment footnotes and tracked over time.
- Where does Incyte's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Incyte's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
